8-K: RxSight CFO Shelley Thunen to Depart, Transition to Consultant

RxSight, Inc. announced that Chief Financial Officer Shelley Thunen will transition from her role, effective by January 31, 2026, and will continue as a consultant.

Summary

• Shelley Thunen is transitioning from her role as Chief Financial Officer (and principal financial and accounting officer) of RxSight, Inc.
• Her departure is effective upon the appointment of a successor or January 31, 2026, whichever comes first.
• Ms. Thunen has agreed to support the company as a consultant subsequent to the transition, with the consulting agreement scheduled to end on December 31, 2026.
• She will remain eligible for an annual cash bonus based on corporate performance in fiscal 2025 and will receive her base salary through the date of transition.
• Under the consulting agreement, Ms. Thunen will be paid non-refundable retainers of $15,000 for each of January, February, and March 2026, and an hourly rate of $500 for her services.
• Her outstanding stock options will continue to vest pursuant to their original terms while she provides services under the consulting agreement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a CFO departure can be seen as a negative, the structured transition plan, consulting agreement, and positive management comments mitigate immediate concerns, suggesting an orderly change rather than an abrupt or problematic one. The continuity provided by the consulting role is a positive.

Positives

• Ms. Thunen will remain with the company as a consultant, ensuring a smooth transition and continued support.
• Her outstanding stock options will continue to vest during her consulting period, incentivizing her continued engagement.
• Management expressed gratitude for her significant contributions, including guiding the company through its IPO in 2021 and growth to over 1,100 Light Delivery Devices (LDDs) in the field and over 250,000 procedures performed.

Negatives

• The departure of a long-serving and highly regarded Chief Financial Officer could introduce an element of uncertainty during the search for a successor.

Future Outlook

The filing primarily focuses on a management change and does not provide specific forward-looking statements regarding financial performance or strategic direction beyond the CFO transition plan.

Management Comments

• "Shelley has been a key and trusted partner throughout some of the most important years in RxSight’s development." Ron Kurtz, CEO and President.
• "Shelley developed and executed on our financial strategy, and over nearly a decade, her leadership and unwavering commitment helped guide RxSight from a pre-commerical company to one with more than 1,100 LDDs in the field and over a quarter million procedures performed." Ron Kurtz, CEO and President.
• "She has shaped the foundation we rely on today, and we are truly grateful for everything she has done for our patients, our customers, and everyone at RxSight." Ron Kurtz, CEO and President.
• "Her judgment, integrity, and dedication helped guide the Company through pivotal events, including our initial public offering in 2021, and positioned RxSight for the opportunities ahead." Andy Corley, Chairman of the Board.
• "The Board is sincerely appreciative of her service and the lasting mark she leaves on the organization." Andy Corley, Chairman of the Board.

Industry Context

The announcement of a CFO transition is a common corporate event. For a medical device company like RxSight, maintaining strong financial leadership is crucial for managing R&D investments, regulatory compliance costs, and commercialization efforts in a competitive ophthalmic market. The company's growth metrics (LDDs in field, procedures performed) indicate a successful commercialization phase, which a new CFO will need to sustain and build upon.

Management Changes

Stakeholder Impact

• Shareholders: Potential short-term uncertainty due to CFO transition, but mitigated by a structured handover and consulting arrangement. Long-term impact depends on the successor's capabilities.
• Employees: Potential for some internal restructuring or changes in financial department leadership.
• Customers/Suppliers: Unlikely to have direct immediate impact, as the core business operations and product offerings remain unchanged.

Next Steps

• Appointment of a successor Chief Financial Officer.
• Ms. Thunen to provide transition services under a consulting agreement until December 31, 2026.

Key Dates

Recommendation

The departure of a long-serving and highly regarded CFO introduces an element of uncertainty, which typically warrants a 'hold' stance until a successor is named and their strategic direction becomes clearer. However, the structured transition plan, including a consulting agreement with the outgoing CFO, mitigates immediate concerns and suggests an orderly process. The company's underlying business strength, as evidenced by its growth metrics (1,100+ LDDs, 250,000+ procedures), remains intact. Investors should monitor the appointment of the new CFO and any subsequent strategic updates.

Keywords

RxSight, RXST, CFO transition, Chief Financial Officer, management change, ophthalmic medical device, Light Adjustable Lens, corporate governance